Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An aggressive malignant tumor arising from trophoblastic cells in the uterus during pregnancy. Approximately half of the cases develop from a complete hydatidiform mole. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.
No clinical trials have been registered for uterine corpus choriocarcinoma.
4 publications have been identified in PubMed for uterine corpus choriocarcinoma. Kisho has analyzed 3 by research type. Research spans Review / Meta-Analysis (67%) and Case Report / Case Series (33%).
Ma J (2025). [PMID: 41195577](https://pubmed.ncbi.nlm.nih.gov/41195577/). *Cancer reports (Hoboken, N.J.)*. [Review / Meta-Analysis]
Mangla M (2025). [PMID: 40917594](https://pubmed.ncbi.nlm.nih.gov/40917594/). *Oncoscience*. [Review / Meta-Analysis]
Idegami D (2024). [PMID: 39015636](https://pubmed.ncbi.nlm.nih.gov/39015636/). *Case Rep Oncol*. [Case Report / Case Series]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 8:42 AM UTC